A Series B funding round from new and existing investors has brought in $18 million for Edimer Pharmaceuticals, a Cambridge, Mass.-based biotech firm specializing in treatments for rare genetic conditions. Edimer will use the money to advance clinical development of ED1200, its experimental drug for X-linked hypohidrotic ectodermal dysplasia.

Related Summaries